ライフサイエンスコーパス: human papillomavirus type 16

1 an parvovirus B19, Chlamydia trachomatis, or human papillomavirus type 16.

2 ing CTL, Th cell, and B cell epitopes of the human papillomavirus type 16.

3 chose cervical carcinoma cells positive for human papillomavirus type 16.

4 of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like p

5 udy using a prototype, lateral-flow test for human papillomavirus type 16, 18, and/or 45 (HPV16/18/45

6 together with DNA encoding the E7 protein of human papillomavirus type 16, a model cervical cancer an

7 with invasive cancers infected by high-risk human papillomavirus type 16 and 18 (rs9296925, P = 0.01

8 effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papilloma

9 evated levels of cellular proliferation, and human papillomavirus type 16 and/or type 18 DNA.

10 in HIV-infected women suggest that although human papillomavirus types 16 and 18 dominate, multiple

11 Maturation of the capsids of human papillomavirus types 16 and 18 proceeds through an

12 ogous promoters, including those of c-H-ras, human papillomavirus types 16 and 18, and HIV type 1.

13 (E3) in the presence of the E6 protein from human papillomavirus types 16 and 18.

14 sing bovine papillomavirus type 1 (BPV1) and human papillomavirus type 16 as model papillomaviruses,

15 hown previously that the E7 oncoprotein from human papillomavirus type 16, dependent upon its binding

16 Human papillomavirus type 16 DNA in oral rinses is commo

17 atinocytes immortalized by transfection with human papillomavirus type-16 Dna became tumorigenic afte

18 d screen for proteins that interact with the human papillomavirus type 16 E1 replication protein.

19 alanine-scanning substitution mutants of the human papillomavirus type 16 E2 N-terminal transactivati

20 The human papillomavirus type 16 E5 oncoprotein (16E5) enhan

21 pulated A549 cells by transfecting them with human papillomavirus type 16 E6 (designated A549-E6) to

22 Two activities of human papillomavirus type 16 E6 (HPV16 E6) are proposed

23 ry-HPV16E6/E7 transgenic mice expressing the human papillomavirus type 16 E6 and E7 oncogenes (HPV-16

24 Expression of the human papillomavirus type 16 E6 and E7 oncogenes initiat

25 Expression of human papillomavirus type 16 E6 and E7 together can esca

26 to interactions of other DNA virus proteins (human papillomavirus type 16 E6 and E7, simian virus 40

27 ry and sufficient for complex formation with human papillomavirus type 16 E6 has been mapped to a 25-

28 We tested a large set of human papillomavirus type 16 E6 mutants for their abilit

29 d by retrovirally mediated expression of the human papillomavirus type 16 E6 protein.

30 hich p53 was eliminated by transduction with human papillomavirus type 16 E6 showed that treatment wi

31 unction induced by stable integration of the human papillomavirus type 16 E6 viral oncoprotein.

32 on in diploid human fibroblasts that express human papillomavirus type 16 E6, which inactivates p53.

33 , following retroviral transduction with the human papillomavirus type 16 E6/E7 oncogenes, are altere

34 repared through stable transfection with the human papillomavirus type-16 E6 gene.

35 s that were acutely damaged by expression of human papillomavirus type-16 E6 protein (*HMEC-E6).

36 ression by retroviral-mediated expression of human papillomavirus type-16 E6 protein (HPV-16 E6) in h

37 sage HMEC (prior to M0) were transduced with human papillomavirus type-16 E6, E7, or E6/E7 by using r

38 cted to cell-bound protein and unaffected by human papillomavirus type 16/E6E7 immortalization and pr

39 We found that human papillomavirus type 16 E7 (HPV-16 E7)- and hydroxy

40 omes from the observation that expression of human papillomavirus type 16 E7 alleviates the M0 prolif

41 We evaluated the effect of linking human papillomavirus type 16 E7 as a model Ag to Mycobac

42 Using human papillomavirus type 16 E7 as a model antigen, we e

43 A human papillomavirus type 16 E7 DNA vaccine with the ope

44 NA vaccine containing an HLA-A2.1-restricted human papillomavirus type 16 E7 epitope (amino acid resi

45 polycomb-mediated epigenetic methylations in human papillomavirus type 16 E7 expressing cells, and in

46 encoding SPI-6 with DNA constructs encoding human papillomavirus type 16 E7 linked to these intracel

47 l human diploid fibroblasts that express the human papillomavirus type 16 E7 oncoprotein have a decre

48 Moreover, we show that the human papillomavirus type 16 E7 oncoprotein stimulates a

49 e defective in binding to adenovirus E1A and human papillomavirus type 16 E7 protein but exhibit wild

50 The human papillomavirus type 16 E7 protein, which binds to

51 biologically relevant, we tested whether the human papillomavirus type 16 E7 protein, which inactivat

52 he coadministration of DNA vaccines encoding human papillomavirus type 16 E7 with siRNA targeting key

53 ated a novel fusion of VP22 with a model Ag, human papillomavirus type 16 E7, in a DNA vaccine that g

54 l fusion of VP22 with a model tumor antigen, human papillomavirus type 16 E7, in a Sindbis virus RNA

55 xin A (ETA(dII)) with a model tumor antigen, human papillomavirus type 16 E7, in the context of a DNA

56 cells, but this function can be replaced by human papillomavirus type 16 E7, which targets pRb for d

57 ne into one with significant potency against human papillomavirus type 16 E7-expressing murine tumors

58 coding MDV-1 VP22 linked to a model antigen, human papillomavirus type 16 E7.

59 it papillomavirus DNA containing an embedded human papillomavirus type 16 E7/82-90 epitope.

60 We tested whether the expression of human papillomavirus type 16 genes E6 and E7 could prote

61 More CTL responses in women with human papillomavirus type 16 (HPV 16) infection without

62 High-risk human papillomavirus type 16 (HPV-16) and HPV-18 are ass

63 The E6 and E7 oncogenes of human papillomavirus type 16 (HPV-16) are sufficient for

64 Essential to the oncogenic properties of human papillomavirus type 16 (HPV-16) are the activities

65 here that the E6 protein from the oncogenic human papillomavirus type 16 (HPV-16) binds to three reg

66 ism by which the E6 and E7 oncoproteins from human papillomavirus type 16 (HPV-16) can be translated

67 Infection with human papillomavirus type 16 (HPV-16) can lead to low- o

68 re tested for immunoglobulin G antibodies to human papillomavirus type 16 (HPV-16) capsids.

69 rved glutamic acid residue at position 39 of human papillomavirus type 16 (HPV-16) E2 to alanine (E39

70 The human papillomavirus type 16 (HPV-16) E5 oncoprotein is

71 The high-risk human papillomavirus type 16 (HPV-16) E5 protein (16E5)

72 The human papillomavirus type 16 (HPV-16) E5 protein is a sm

73 Human papillomavirus type 16 (HPV-16) E6 (16E6) binds th

74 Human papillomavirus type 16 (HPV-16) E6 activates telom

75 Retrovirally mediated expression of human papillomavirus type 16 (HPV-16) E6 and antisense o

76 Cells expressing human papillomavirus type 16 (HPV-16) E6 and E7 proteins

77 Human papillomavirus type 16 (HPV-16) E6 augmented the k

78 Human papillomavirus type 16 (HPV-16) E6 has been shown

79 of human skin fibroblasts by expressing the human papillomavirus type 16 (HPV-16) E6 oncoprotein to

80 Here we show that expression of the human papillomavirus type 16 (HPV-16) E6 protein activat

81 Three naturally occurring variant human papillomavirus type 16 (HPV-16) E6 proteins, which

82 live vector, we show that the expression of human papillomavirus type 16 (HPV-16) E7 fused to a nonh

83 The human papillomavirus type 16 (HPV-16) E7 gene encodes a

84 Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rap

85 The human papillomavirus type 16 (HPV-16) E7 oncoprotein rap

86 trosomal marker, with a model tumor antigen, human papillomavirus type 16 (HPV-16) E7, in a DNA vacci

87 Cells expressing human papillomavirus type 16 (HPV-16) E7, similar to tho

88 The human papillomavirus type 16 (HPV-16) genome is commonly

89 Human papillomavirus type 16 (HPV-16) has developed nume

90 Human papillomavirus type 16 (HPV-16) infection is posit

91 tionship between serum antibody response and human papillomavirus type 16 (HPV-16) infection, a cohor

92 Viral load may influence the course of human papillomavirus type 16 (HPV-16) infection.

93 anal cancers are attributable to persistent human papillomavirus type 16 (HPV-16) infection.

94 Integration of human papillomavirus type 16 (HPV-16) into the host DNA

95 Human papillomavirus type 16 (HPV-16) is associated with

96 high-risk cervical cancer-associated strain human papillomavirus type 16 (HPV-16) is described here.

97 The production of the human papillomavirus type 16 (HPV-16) is intimately tied

98 Persistent infection with human papillomavirus type 16 (HPV-16) is strongly associ

99 Human papillomavirus type 16 (HPV-16) is strongly associ

100 The human papillomavirus type 16 (HPV-16) oncoproteins, E6 a

101 on would occur in human cells transformed by human papillomavirus type 16 (HPV-16) oncoproteins.

102 Because the human papillomavirus type 16 (HPV-16) p97 promoter has s

103 s detected in keratinocytes transfected with human papillomavirus type 16 (HPV-16) plasmid DNA.

104 The study of human papillomavirus type 16 (HPV-16) replication has be

105 We examined intratype human papillomavirus type 16 (HPV-16) sequence variation

106 ompared for their capacities to detect mixed human papillomavirus type 16 (HPV-16) variant infections

107 rological assays for measuring antibodies to human papillomavirus type 16 (HPV-16) virus-like particl

108 sensitive luminescence immunoassay (LIA) for human papillomavirus type 16 (HPV-16) was developed and

109 Human papillomavirus type 16 (HPV-16), a DNA tumor virus

110 ignal, we found that the E7 oncoprotein from human papillomavirus type 16 (HPV-16), the etiological a

111 ly 20 percent of adults become infected with human papillomavirus type 16 (HPV-16).

112 tiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) i

113 teins from high-risk human papillomaviruses (human papillomavirus type 16 [HPV-16] and HPV-18) are mu

114 ractions between the L2 protein of high-risk human papillomavirus type 16 (HPV16) and nuclear import

115 Human papillomavirus type 16 (HPV16) and other high-risk

116 Human papillomavirus type 16 (HPV16) and other oncogenic

117 blished a cell-free in vitro system to study human papillomavirus type 16 (HPV16) assembly, a poorly

118 The E7 gene product of human papillomavirus type 16 (HPV16) binds to the retino

119 inocytes (HKc) immortalized with full-length human papillomavirus type 16 (HPV16) DNA (HKc/HPV16), bu

120 ts homology with the solved structure of the human papillomavirus type 16 (HPV16) domain.

121 tro binding assays to map the domains of the human papillomavirus type 16 (HPV16) E1 and E2 proteins

122 Random mutagenesis of human papillomavirus type 16 (HPV16) E1 was used to gene

123 no acids within the N-terminal domain of the human papillomavirus type 16 (HPV16) E2 protein.

124 The human papillomavirus type 16 (HPV16) E5 protein associat

125 It was previously reported that the human papillomavirus type 16 (HPV16) E6 oncoprotein may

126 (E6-targeted protein 1) as a novel high-risk human papillomavirus type 16 (HPV16) E6-binding protein.

127 Proteomic identification of human papillomavirus type 16 (HPV16) E6-interacting prot

128 cells (MECs) are efficiently immortalized by human papillomavirus type 16 (HPV16) E6.

129 e (hTERT) in keratinocytes can be induced by human papillomavirus type 16 (HPV16) E6/E6AP ubiquitin l

130 We previously observed that high-risk human papillomavirus type 16 (HPV16) E7 expression leads

131 ary outgrowth from breast organoids with the human papillomavirus type 16 (HPV16) E7 gene.

132 The human papillomavirus type 16 (HPV16) E7 is a major viral

133 Human papillomavirus type 16 (HPV16) E7 is a viral oncop

134 The high-risk human papillomavirus type 16 (HPV16) E7 oncoprotein indu

135 e simian virus 40 (SV40) large T antigen and human papillomavirus type 16 (HPV16) E7 protein also bin

136 r to identify cellular factors that regulate human papillomavirus type 16 (HPV16) gene expression, ce

137 In this study, we map the elements in the human papillomavirus type 16 (HPV16) genome that can sub

138 xperiments investigating the capacity of the human papillomavirus type 16 (HPV16) genome to replicate

139 Human papillomavirus type 16 (HPV16) has been identified

140 Human papillomavirus type 16 (HPV16) infection is a majo

141 Human papillomavirus type 16 (HPV16) infection is causin

142 Although most cervical human papillomavirus type 16 (HPV16) infections become u

143 Human papillomavirus type 16 (HPV16) infects cervical ep

144 The E6 oncoprotein of high-risk human papillomavirus type 16 (HPV16) interacts with seve

145 Given that the integration of human papillomavirus type 16 (HPV16) into the host genom

146 Cell invasion by human papillomavirus type 16 (HPV16) is a complex proces

147 Persistent infection with human papillomavirus type 16 (HPV16) is a primary etiolo

148 The E5 protein of human papillomavirus type 16 (HPV16) is a small hydropho

149 High-risk human papillomavirus type 16 (HPV16) is the primary caus

150 Human papillomavirus type 16 (HPV16) is the primary etio

151 Human papillomavirus type 16 (HPV16) is the primary etio

152 Expression of human papillomavirus type 16 (HPV16) L1 and L2 together

153 Vaccination with human papillomavirus type 16 (HPV16) L1 virus-like parti

154 of BPV1, but not coexpression of BPV1 L1 and human papillomavirus type 16 (HPV16) L2.

155 During cellular invasion, human papillomavirus type 16 (HPV16) must transfer its v

156 Several human papillomavirus type 16 (HPV16) oncoproteins contri

157 The safety and immunogenicity of the human papillomavirus type 16 (HPV16) or HPV18 (HPV16/18)

158 Oncogenic human papillomavirus type 16 (HPV16) or type 18 (HPV18)

159 ents infection of the mouse genital tract by human papillomavirus type 16 (HPV16) pseudovirions.

160 o examine the rate of and risks for cervical human papillomavirus type 16 (HPV16) redetection in wome

161 0, H16.U4, and H16.V5, neutralize pseudotype human papillomavirus type 16 (HPV16) virions in vitro.

162 Human papillomavirus type 16 (HPV16) virus-like particle

163 primary causative agent of cervical cancer, human papillomavirus type 16 (HPV16), must first cross t

164 Pseudovirions of human papillomavirus type 16 (HPV16), the principal etio

165 ortal 184A1 HMEC line to the viral oncogenes human papillomavirus type 16 (HPV16)-E6, -E7, or SV40T,

166 (LEEP) and who had a baseline infection with human papillomavirus type 16 (HPV16).

167 Human papillomavirus type-16 (HPV16) L1 virus-like parti

168 High risk human papillomavirus types 16 (HPV16) and 18 (HPV18) can

169 DEK message and protein levels in senescing human papillomavirus type 16- (HPV16-) and HPV18-positiv

170 n repair (NER) capacity of normal (NHOK) and human papillomavirus type-16 immortalized oral keratinoc

171 e epidermal growth factor receptor (EGFR) in human papillomavirus type 16-immortalized human keratino

172 CIN II/III among American Indian women were human papillomavirus type 16 infection (adjusted odds ra

173 Human papillomavirus type 16 is a common sexually transm

174 The E5 protein of human papillomavirus type 16 is a small, hydrophobic pro

175 ructure of small virus-like particles of the human papillomavirus type 16 L1 protein to generate an a

176 Since human papillomavirus type 16 L1 virus-like particles (HP

177 tes of a single papillomavirus type (such as human papillomavirus type 16) may contribute to a collec

178 corneal endothelial cells, transformed with human papillomavirus type 16 oncogenes E6 and E7, showed

179 A mouse model involving the human papillomavirus type-16 oncogenes develops cervical

180 Recently, the high-risk human papillomavirus type 16 oncoprotein E6 was identifi

181 Expression of both human papillomavirus type 16 oncoproteins, E6 and E7, in

182 The E7 oncoprotein of human papillomavirus type 16 promotes cell proliferation

183 ciation between serum antibodies against the human papillomavirus type 16 protein E6 and anal cancer

184 Human papillomavirus type 16 proteins E6 and E7 have bee

185 However, we found that human papillomavirus type 16 pseudovirions efficiently b

186 c E2F expression or Rb inactivation by E7 of human papillomavirus type 16 signals apoptosis by induci

187 We report the isolation and propagation of human papillomavirus type 16, the main agent of cervical

188 Mice that express transgenes for human papillomavirus type 16 under a keratin 14 promoter

189 for optimal Ab responses to a model vaccine, human papillomavirus type 16 virus-like particles (HPV 1

190 use with transgenes for the highly oncogenic human papillomavirus type 16, we asked whether a diet hi